Verrica Pharmaceuticals Inc VRCA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $6.53
- Day Range
- $6.26–6.57
- 52-Week Range
- $3.28–9.82
- Bid/Ask
- $6.15 / $6.85
- Shares Outstanding
- 17.18M
- Market Cap
- $107.54M
- Volume/Avg
- 14,050 / 66,910
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.22
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 76
- Website
- https://www.verrica.com
Valuation
|
Metric
|
VRCA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.49 |
Price/Sales | 2.22 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VRCA
|
|---|---|
Quick Ratio | 1.75 |
Current Ratio | 2.10 |
Interest Coverage | −2.27 |
Quick Ratio
VRCA
Profitability
|
Metric
|
VRCA
|
|---|---|
Return on Assets (Normalized) | −36.65% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −47.97% |
Return on Assets
VRCA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@^<dzSW | LOCK|@!$t? | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#>&YG<T | LOCK|glhJ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|q>vK&^w | LOCK|v%B | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>TQk$> | LOCK|<?VY | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%$X^H# | LOCK|Gp | $36B | |||
| Moderna Inc
MRNA
| LOCK|fm$H^@& | LOCK|Db% | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#r#<GX& | LOCK|s#r& | $25B | |||
| Incyte Corp
INCY
| LOCK|sz>Cp& | LOCK|gy | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|n>?>LZ | LOCK|wN | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|S$!Kx&! | LOCK|Tr | $17B |
United States